After the Reverse Split, we were worth 5x the price of a CYDY share.
Management has done much to advance the company since then.
The result? Today, HGEN is still worth 5x the price of a CYDY share.
Notice I said that management has done much. I didn't say they have accomplished much, on the regulatory approval front.
It could be that the FDA/NIH think our LIVE-AIR updated data is over-stated. That does not mean that the ACTIV-5 trial results of lenzilumab will fail to prove that lenz is still the most effective therapeutic, by far. That should be borne out of by our LIVE-AIR peer review too, even if we have to accommodate the FDA with a change in our statistical analysis.
If that's the case, I hope our clinical investigators have reviewed our LIVE-AIR data with the statistical model the FDA/NIH is using, and that we can look forward to a Lancet peer review publication even before the NIH reports topline data. I hope that publication will also be sufficient to secure international Regulatory approvals, as well.
I hope you resume a position here. The LIVE-AIR updated data peer review, as well as the NIH topline data, could be released at any time. Good luck on whatever you choose to do.